TOPLINE:
Prenatal exposure to triptans, alone or with other migraine medications, was not associated with a significantly increased risk for neurodevelopmental disorders (NDDs) in children born to mothers with a history of migraine in a new study.
METHODOLOGY:
- Researchers conducted a registry-based cohort study in Norway, using data from multiple national health registries between 2008 and 2023.
- The study included more than 26,000 children born to mothers with migraine, with the children followed up to 14 years of age. Among the mothers, 81% used triptans and 19% did not.
- Prenatal exposure to triptans and other antimigraine medications was determined by prescription fills from 12 months before pregnancy until delivery. Exposure was grouped as low use (42%), short-term low use (31%), moderate use (21%), and high use…